Jan Torleif Pedersen
Chief Science Officer & DirectorDr. Jan Torleif Pedersen, Ph.D. & M.Sc., serves as a Director at Bright Minds Biosciences Inc. since April 27, 2022 and has been Chief Science Officer since September 22, 2022. He also served as its Interim Chief Science Officer since June 26, 2022 until December 2022. He is an innovative and highly experienced leader in drug discovery research, with vast expertise in neuroscience research management. Dr. Pedersen’s academic interests include neurodegeneration, bioinformatics, biophysics and drug discovery R&D. He is the founder of Torleif Science ApS, a consultancy company aimed at delivering innovation and new ideas in neuroscience. Prior to that, Dr. Pedersen spent several years at Lundbeck, a global pharmaceutical company specialized in brain diseases, in positions of increasing responsibility, including building its neurodegeneration/Alzheimer’s disease pipeline, and bringing research programs to the clinic. Dr. Pedersen received an MSc in Chemistry from DTU – Technical University of Denmark, and a PhD in biophysics from the University of Bath.
Positions
- Company NameBright Minds Biosciences Inc.Stock CodeDRUGPositionChief Science Officer & DirectorColleagues
- IMIan McDonaldCo-Founder, CEO, President & Director
- RERyan E. S. K. CheungCFO & Corporate Secretary
- AVAlex VasilkevichCOO & Senior Scientific Officer
- ELEmer LeahyConsultant
- NCNils Christian BottlerIndependent Director
- JFJeremy FryzukIndependent Director
- HYHerbert Y. MeltzerMember of Scientific Advisory Board
